November 2025 in “Mendeley Data” This study found that tofacitinib and baricitinib, when administered with unorthodox weight-stratified dosing in pediatric patients with moderate-to-severe AA, showed comparable efficacy and tolerability, though baricitinib's efficacy decreased with non-standard dosing.
June 2024 in “European neuropsychopharmacology”
17 citations
,
May 2011 in “Movement Disorders” Finasteride significantly reduced tics and obsessive-compulsive symptoms in patients with Tourette syndrome.
3 citations
,
April 2010 in “Clinical Neuropharmacology” In this case report, a 75-year-old man with benign essential blepharospasm and Parkinson disease experienced significant symptom relief from dystonia after starting finasteride, suggesting it may be a potential therapeutic option.
January 2023 in “Brazilian Journals Editora eBooks” Girls with Autism Spectrum Disorder may show different symptoms than boys, leading to missed or delayed diagnoses.
October 2019 in “Academic medicine” This narrative recounts a medical student's early experiences of confidence in diagnostics, transforming into a commitment to honesty and empathy in patient care after a challenging clinical encounter.
3 citations
,
May 2018 in “Psychiatry and Clinical Psychopharmacology” In this report, an 18-year-old female with trichotillomania was successfully treated using the glutamate modulator n-acetylcysteine.
July 2025 in “Journal of Investigative Dermatology” TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.
17 citations
,
August 2019 in “Archives of Cardiovascular Diseases” In this study, the authors observed that testosterone therapy shortened the QTc interval and normalized T-wave morphology in men with acquired LQTS or TdP linked to hypogonadism, suggesting testosterone may be helpful in treatment.
2 citations
,
November 2008 This article discusses the implementation of problem-based learning in a ninth-grade biology class in Singapore, highlighting the use of authentic, student-driven inquiries to explore topics like nutrition and health without reporting new empirical results.
2 citations
,
April 2024 in “Journal of Clinical Psychopharmacology” In this study, dutasteride 1 mg daily reduced heavy drinking days and drinks per week among treatment-seeking men, particularly benefiting those with high baseline drinking to cope motives.
12 citations
,
September 2015 in “Drug Design Development and Therapy” This study found that the DOX derivative AD198 more effectively inhibited cell viability and induced apoptosis in canine cancer cell lines K9TCC and K9OSA compared to DOX in vitro.
52 citations
,
October 1997 in “American Journal of Psychiatry” This discussion reviews the complexities of trichotillomania's symptoms, pathology, and treatment, but reports no new research findings; it highlights a specific illustrative case.
12 citations
,
February 2017 in “Journal of neuroscience research” This study suggests that extrasynaptic δGABA-A receptors may have a protective role in modulating the severity of catamenial-like seizures by influencing neurosteroid and benzodiazepine responses in mice.
September 2021 in “Physiology News” The abstract does not provide any research findings or conclusions to summarize, focusing instead on color and logo specifications.
September 2018 in “Boletín médico del Hospital Infantil de México” This article examines the care and health challenges faced by transgender or gender incongruence individuals, reporting no new clinical results; it highlights the importance of an individualized approach for optimizing well-being.
April 2026 in “Therapeutic Advances in Drug Safety” This study developed a new clustering model to improve detection of drug-induced cognitive disorder risk signals, finding that it identified drugs with moderate risk signals, like Carbidopa/Levodopa, missed by traditional methods, enhancing clinical assessment comprehensiveness.
1 citations
,
November 2001 in “Acc Current Journal Review” This review found that 5α‐reductase inhibitors were associated with slightly increased rates of decreased libido, erectile and ejaculatory dysfunction, gynecomastia, and mood disorders compared to placebo, though their long-term effects remain unclear.
December 2023 in “Current psychosomatic research” This study suggests that psychological interventions such as mindfulness therapy, yoga, cognitive-behavioral therapy, and motivational interviewing may increase the quality of life for women with polycystic ovarian syndrome.
35 citations
,
January 2012 in “The Journal of Sexual Medicine” This review examines various androgen deprivation therapy methods for advanced prostate cancer, highlighting benefits and potential cardiovascular and sexual adverse effects, but reports no new clinical results.
December 2024 in “Journal of Clinical Medicine” This review explores the hormonal factors linking polycystic ovary syndrome and psychiatric disorders, such as eating disorders, emphasizing a bidirectional relationship that necessitates a multidisciplinary treatment approach; it reports no new clinical results.
December 2017 in “Journal of the Hellenic Veterinary Medical Society” This article reviews canine acrai lick dermatitis, detailing its multifactorial causes and treatments, but does not present new experimental results.
September 2024 in “Complementary Medicine Research” Traditional Persian medicine helped a woman with resistant hyperthyroidism improve and stabilize her condition.
14 citations
,
October 2015 in “Neurochemistry International” This study found that letrozole, an aromatase inhibitor, reduced the incidence and severity of PTZ-induced kindling seizures in mice, potentially due to its effects on 17β-estradiol and neurosteroid synthesis.
This case study documents a 55-year-old male with advanced NSCLC who experienced toe-predominant paronychia and a papulopustular rash following dacomitinib treatment, with the causality tools indicating a "probable" link, yet the therapy continued successfully without dosage alteration.
November 2025 in “Mendeley Data” In this study, tofacitinib and baricitinib showed comparable efficacy and tolerability under unorthodox weight-stratified dosing in pediatric patients with moderate-to-severe alopecia areata over 24 weeks; however, the unorthodox baricitinib regimen yielded a lower effectiveness in severe cases, emphasizing the importance of adherence to guideline-recommended dosing.
98 citations
,
July 2006 in “Neuropsychopharmacology” August 2025 in “Brazilian Journal of Hair Health” This study found that 29.6% of patients seeking treatment for hair loss meet the criteria for hair-related body dysmorphic disorder, significantly higher than in general dermatology patients.
4 citations
,
November 2020 in “Acta Dermato Venereologica” In this study, patients with specific skin and scalp conditions, including eczematous lesions, showed significant improvement after two weeks of oral tofacitinib treatment, as evidenced by changes in the trunk lesions.
January 1975 in “NJEA Review” This Phase II study found that BAY 43-9006, given at 400 mg orally twice daily, led to stable disease in 30% and tumor reduction in 40% of renal cell carcinoma patients.